Catalyst Event
Merck and Co Inc (MRK) · Earnings Release
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/30/2026, 12:00:00 AM
First quarter 2026 earnings release scheduled for April 30, 2026. Medium importance is estimated based on typical price volatility during earnings announcements, and the release is scheduled.
Korean Translation
2026년 4월 30일, 2026년 1분기 실적 발표 예정됨. 실적 발표 시의 과거 주가 변동성을 고려하여 중간 중요도로 평가되며 발표가 예정됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release is scheduled; medium importance is estimated based on expected >=5% price impact.
4/30/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Other
The FDA's Oncologic Drugs Advisory Committee (ODAC) is scheduled to meet on 2026-04-30 to review applications for camizestrant for breast cancer and a label expansion for Truqap in prostate cancer, scheduled.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
FDA decision on oral weight-loss drug orforglipron is expected; high importance is estimated due to potential for >=10% price impact.
4/10/2026, 12:00:00 AM